Taking the fight to cancer
Amersham – GE Healthcare intends to remain a major force in cancer therapy. Based in London, the health business of the US technology giant announced it will be reserving €730m of its total R&D budget over the next five years for cancer-related topics. Besides advancing molecular imaging, the money will go into the manufacture of biopharmaceuticals and biomarkers for cancer research. GE Healthcare employs 2,600 people in the UK. “We are committed to tackling cancer. We are devoting an even greater share of our R&D budget to continue developing new oncology solutions,” said John Dineen, President and CEO of GE Healthcare. The investment will focus on several biotech areas in the company. GE’s Clarient business is investigating a new biomarker (TLE3) for identifying patients who will not respond to Taxane therapy. TLE3 is being developed for breast cancer, lung cancer and ovarian cancer. GE Global Research scientists are working on diagnostic multiplexing that could allow pathologists to conduct more than 50 different stains on a single tissue section. And in collaboration with the University of California in San Francisco (US), GE Healthcare and GE Global Research are developing new 13C-based agents for metabolic imaging.